KainosMed Receives Approval for Phase 2 Trial Plan of Parkinson's Disease Treatment 'KM-819'
[Asia Economy Reporter Minwoo Lee] Kainosmed announced on the 22nd that it has received approval from the Ministry of Food and Drug Safety for the phase 2 clinical trial plan of KM-819, a treatment for multiple system atrophy (MSA). Multiple system atrophy is a type of disease classified under Parkinsonian syndromes.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- [Lee Jaemyung Administration One Year] "A Breakwater in Crisis, a Blade Against Waste"... Planning Ministry's Fiscal Tightening Earns High Marks
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The company stated, "The investigational drug KM-819 is expected to protect dopamine-producing neurons from cell death by inhibiting the overexpression of FAF1, which induces cell apoptosis, thereby slowing the pathological progression of multiple system atrophy through a novel pharmacological mechanism." They added, "In this clinical trial, it is expected that the KM-819 treatment group will show a clinically significant slower progression of multiple system atrophy and improved neurological assessment results compared to the control group."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
